Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons

• Main Authors: Javier Donate-Correa, Víctor G. Tagua, Carla Ferri, Ernesto Martín-Núñez, Carolina Hernández-Carballo, Pablo Ureña-Torres, Marta Ruiz-Ortega, Alberto Ortiz, Carmen Mora-Fernández, Juan F. Navarro-González
• Format: Article
• Language: English
• Published: MDPI AG 2019-02-01
• Series: Journal of Clinical Medicine
• Subjects: pentoxifylline; diabetic kidney disease; inflammation; Klotho
• Online Access: https://www.mdpi.com/2077-0383/8/3/287

Diabetic kidney disease is one of the most relevant complications in diabetes mellitus patients, which constitutes the main cause of end-stage renal disease in the western world. Delaying the progression of this pathology requires new strategies that, in addition to the control of traditional risk factors (glycemia and blood pressure), specifically target the primary pathogenic mechanisms. Nowadays, inflammation is recognized as a critical novel pathogenic factor in the development and progression of renal injury in diabetes mellitus. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with rheologic properties clinically used for more than 30 years in the treatment of peripheral vascular disease. In addition, this compound also exerts anti-inflammatory actions. In the context of diabetic kidney disease, pentoxifylline has shown significant antiproteinuric effects and a delay in the loss of estimated glomerular filtration rate, although at the present time there is no definitive evidence regarding renal outcomes. Moreover, recent studies have reported that this drug can be associated with a positive impact on new factors related to kidney health, such as Klotho. The use of pentoxifylline as renoprotective therapy for patients with diabetic kidney disease represents a new example of drug repositioning.